Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

BACKGROUND: The combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of patients infected with HCV genotype 1 has led to significantly increased rates of sustained virological response (SVR) in phase III trials. There is only limited data regarding the safe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Wehmeyer, Malte H, Eißing, Friederike, Jordan, Sabine, Röder, Claudia, Hennigs, Annette, Degen, Olaf, Hüfner, Anja, Hertling, Sandra, Schmiedel, Stefan, Sterneck, Martina, van Lunzen, Jan, Lohse, Ansgar W, zur Wiesch, Julian Schulze, Lüth, Stefan
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102246/
https://ncbi.nlm.nih.gov/pubmed/24884400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-14-87
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items